Clinical outcomes from an open-label study of edivoxetine use in pediatric patients with attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 23, Issue 3, 2013, Pages 200-207

  Jin, Ling ^a   Xu, Wen ^a   Krefetz, David ^b   Gruener, Daniel ^b   Kielbasa, William ^a   Tauscher Wisniewski, Sitra ^a   Allen, Albert J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b CRI Worldwide   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDIVOXETINE;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; BODY WEIGHT; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DECREASED APPETITE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; LABORATORY TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MANIA; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CHILD; FEMALE; HEART RATE; HUMANS; MALE; MORPHOLINES; PHENYLETHYL ALCOHOL; PSYCHIATRIC STATUS RATING SCALES; SUICIDAL IDEATION; TREATMENT OUTCOME;

EID: 84876730742     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2012.0016     Document Type: Article

References (20)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Ball SG, Dellva MA, D'Souza DN, Marangell LB, Russell JM, Goldberger C: A double-blind, placebo-controlled study of augmentation with LY2216684 for major depressive disorder patients who are partial responders to selective serotonin reuptake inhibitors (abstract). Vienna, Austria: 10th International Forum on Mood and Anxiety Disorders (IFMAD); 2010.
3. Centers for Disease Control and Prevention: Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children-United States, 2003-2007. MMWR Morb Mortal Wkly Rep 59: 1439-1443, 2010.
4. Dubé S, Dellva MA, Jones M, Kielbasa W, Padich R, Saha A, Rao P: A study of the effects of LY2216684, a selective norepinephrine reuptake inhibitor, in the treatment of major depression. J Psychiatr Res 44: 356-363, 2010.
5. DuPaul GJ: Parent and teacher ratings of ADHD symptoms: Psychometric properties in a community-based sample. J Clin Child Psychol 20: 245-253, 1991.
6. Faries DE, Yalcin I, Harder D, Heiligenstein JH: Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 5: 107-115, 2001.
7. Funck-Brentano C, Jaillon P: Rate-corrected QT interval: Techniques and limitations. Am J Cardiol 72: 17B-22B, 1993.
8. Garnock-Jones KP, Keating GM: Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs 24: 85-88, 2010.
9. Guy W: ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: United States Department of Health, Education, and Welfare; 1976.
10. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36: 980-988, 1997.
11. Kielbasa W, Luffer-Atlas D, Wondmagegnehu E, Mitchell MI, Turik MA: Investigation of the potential for PK interactions between LY2216684, a norepinephrine reuptake inhibitor, and selective serotonin reuptake inhibitor antidepressants in humans (abstract). Dallas, TX: 112th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 2011.
12. Kielbasa W, Quinlan T, Jin L, Xu W, Lachno DR, Dean RA, and Allen AJ : Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 22: 1-8, 2012.
13. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo controlled, dose-response study. Pediatrics 108: E83-91, 2001.
14. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents: The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114 (2 Suppl 4th Report): 555-576, 2004.
15. Pangallo B, Dellva MA, D'Souza DN, Essink B, Russell J, Goldberger C: A randomized, double-blind study comparing LY2216684 and placebo in the treatment of major depressive disorder. J Psychiatr Res 45: 748-755, 2011.
16. Pliszka S, AACAP Work Group on Quality Issues: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46: 894-921, 2007.
17. Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164: 1035-1043, 2007.
18. Sauer JM, Ring BJ, Witcher JW: Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44: 571-590, 2005.
19. Spencer TJ: ADHD and comorbidity in childhood. J Clin Psychiatry 67 (Suppl 8): 27-31, 2006.
20. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J: Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 26: 729-740, 2003.